公开(公告)号：US20160193333A1

公开(公告)日：2016-07-07

申请号：US14911387

申请日：2014-08-13

申请人： Charis PAPAVASSILIS ,  Oliver SANDER ,  Tomohiro SHIMA ,  Susumu KITAMURA

发明人： Charis Papavassilis ,  Oliver SANDER ,  Tomohiro SHIMA ,  Susumu KITAMURA

IPC分类号： A61K39/395 ,  A61K45/06 ,  C07K16/24

CPC分类号： A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/244 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： The disclosure is directed to methods, treatment regimens, uses, kits and therapies for treating Generalized Pustular Psoriasis (GPP). These methods, treatment regimens, uses, kits and therapies utilize, inter alia, administration of an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab. Additionally disclosed are improved methods for treating plaque-type psoriasis that utilize up-titration and down-titration of the IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, as well as modification of dose frequency. Further disclosed are methods of treating palmoplantar pustular psoriasis using the disclosed IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab.

摘要翻译： 本公开涉及用于治疗广泛性脓疱性银屑病（GPP）的方法，治疗方案，用途，试剂盒和治疗方法。 这些方法，治疗方案，用途，试剂盒和治疗方法尤其利用IL-17拮抗剂（例如IL-17抗体，例如塞苏单抗）的施用。 另外公开了用于治疗斑块型银屑病的改进方法，其利用IL-17拮抗剂（例如IL-17抗体例如塞苏单抗）的上滴定和下调，以及剂量频率的修改。 进一步公开的是使用所公开的IL-17拮抗剂，例如IL-17抗体（例如塞苏单抗）治疗掌跖脓疱性牛皮癣的方法。

公开(公告)号：US10434172B2

公开(公告)日：2019-10-08

申请号：US14911387

申请日：2014-08-13

申请人： Charis Papavassilis ,  Oliver Sander ,  Tomohiro Shima ,  Susumu Kitamura

发明人： Charis Papavassilis ,  Oliver Sander ,  Tomohiro Shima ,  Susumu Kitamura

IPC分类号： A61K39/395 ,  C07K16/24 ,  A61K45/06 ,  A61K39/00

摘要： The disclosure is directed to methods, treatment regimens, uses, kits and therapies for treating Generalized Pustular Psoriasis (GPP). These methods, treatment regimens, uses, kits and therapies utilize, inter alia, administration of an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab. Additionally disclosed are improved methods for treating plaque-type psoriasis that utilize up-titration and down-titration of the IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, as well as modification of dose frequency. Further disclosed are methods of treating palmoplantar pustular psoriasis using the disclosed IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab.

公开(公告)号：US09717791B2

公开(公告)日：2017-08-01

申请号：US13876367

申请日：2011-10-07

申请人： Achim Guettner ,  Matthias Machacek ,  Charis Papavassilis ,  Oliver Sander

发明人： Achim Guettner ,  Matthias Machacek ,  Charis Papavassilis ,  Oliver Sander

IPC分类号： A61K39/395 ,  C07K16/24 ,  A61K39/00

CPC分类号： A61K39/3955 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/244 ,  C07K2317/34 ,  C07K2317/76

摘要： The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.